U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O5
Molecular Weight 362.4599
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCORTISONE

SMILES

C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO

InChI

InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H30O5
Molecular Weight 362.4599
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers.
1999 Aug
New weakness in a critically ill patient.
1999 Dec
Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.
1999 Dec 24
Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes.
1999 Mar
Delayed generalized allergic reactions to corticosteroids.
2000
Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin.
2000 Apr
[Respiratory muscle weakness after prolonged use of hydrocortisone and pancuronium bromide].
2000 Jan
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
[A senile case of acute necrotizing myopathy presenting prolonged severe muscle paralysis due to high dose glucocorticoid and muscle relaxant].
2000 Mar
Role of erythropoietin in cortisol-induced hypertension.
2000 Mar
Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure.
2000 Nov
Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.
2000 Sep
Effect of ruminations on the saliva cortisol response to a social stressor.
2001 Apr
Enhanced memory for emotional material following stress-level cortisol treatment in humans.
2001 Apr
Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals.
2001 Apr
Gender differences in age-related changes in HPA axis reactivity.
2001 Apr
Psychophysiological responses to the Stroop Task after a maximal cycle ergometry in elite sportsmen and physically active subjects.
2001 Feb
Circulatory support of the sick preterm infant.
2001 Feb
Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation.
2001 Feb
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.
2001 Feb
Postnatal glucocorticoids in very preterm infants: "the good, the bad, and the ugly"?
2001 Feb
Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor.
2001 Feb
Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade.
2001 Feb
Oral glucose augments the counterregulatory hormone response during insulin-induced hypoglycemia in humans.
2001 Feb
The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis.
2001 Feb
Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies.
2001 Feb
Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects.
2001 Feb
Green fluorescent protein mutant as label in homogeneous assays for biomolecules.
2001 Feb 1
Hormonal regulation of mitochondrial Tim23 gene expression in the mouse mammary gland.
2001 Feb 14
Carbachol induces homologous steroidogenic refractoriness of bovine fasciculata-reticularis cells.
2001 Feb 14
Thapsigargin inhibits angiogenesis in the rat isolated aorta: studies on the role of intracellular calcium pools.
2001 Feb 16
Post-dexamethasone cortisol level and memory performance in elderly depressed patients.
2001 Feb 2
Inhibition of cortisol secretion in dispersed head kidney cells of rainbow trout (Oncorhynchus mykiss) by endosulfan, an organochlorine pesticide.
2001 Jan
Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways.
2001 Jan
Net amino acid flux across the fetal liver and placenta during spontaneous ovine parturition.
2001 Jan
Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia.
2001 Jan
Effects of cortisol on chloride cells in the gill epithelium of Japanese eel, Anguilla japonica.
2001 Jan
Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis.
2001 Jan
Adrenocortical dysfunction following etomidate induction in emergency department patients.
2001 Jan
Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases.
2001 Jan
Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.
2001 Jan
Reference intervals for glucose, beta-cell polypeptides, and counterregulatory factors during prolonged fasting.
2001 Jan
Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects.
2001 Jan 1
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.
2001 Jan 1
Neural correlates of maternal separation in rhesus monkeys.
2001 Jan 15
Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni.
2001 Jan 15
Crystallization of hydrocortisone acetate: influence of polymers.
2001 Jan 16
Monohydroxylation and esterification as determinants of the effects of cis- and trans-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro.
2001 Jan 16
The use of chitosan gels as matrices for electrically-modulated drug delivery.
2001 Jan 29
Patterns of integrin expression in a human mandibular explant model of osteoblast differentiation.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
In Vitro Use Guide
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:55:37 UTC 2019
Edited
by admin
on Mon Oct 21 20:55:37 UTC 2019
Record UNII
WI4X0X7BPJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCORTISONE
EP   GREEN BOOK   HSDB   II   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
HYDROCORTISONE [ORANGE BOOK]
Common Name English
HYDROCORTISONE [WHO-IP]
Common Name English
HYDROCORTISONE ACETATE IMPURITY A [EP]
Common Name English
HYDROCORTISONE COMPONENT OF CALMURID HC
Common Name English
HYDROCORTISONE [USP-RS]
Common Name English
PROCTOCORT
Brand Name English
ANUSOL HC
Brand Name English
GLYCORT
Brand Name English
HYDROCORTISONE COMPONENT OF PYOCIDIN
Common Name English
CORTENEMA
Brand Name English
HYDROCORTISONE [II]
Common Name English
OTOCORT COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF OTOBIOTIC
Common Name English
HYDROCORTISONE [USP]
Common Name English
HYDROCORTISONE SODIUM SUCCINATE IMPURITY A [EP]
Common Name English
TEXACORT
Brand Name English
PLENADREN
Brand Name English
HYDROCORTISONE COMPONENT OF OTICAIR
Common Name English
CORTEF
Brand Name English
HYDROCORTISONE [VANDF]
Common Name English
CORTISOL
Common Name English
AEROSEB-HC
Brand Name English
PREGN-4-ENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA.)-
Systematic Name English
NOGENIC HC
Brand Name English
HYDROCORTISONE [MART.]
Common Name English
STIE-CORT
Brand Name English
EPICORT
Brand Name English
OTOBIONE COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE [MI]
Common Name English
HYDROCORTONE
Brand Name English
HYDROCORTISONE [GREEN BOOK]
Common Name English
COLOCORT
Brand Name English
HYDROCORTISONE COMPONENT OF OTOBIONE
Common Name English
PEDIOTIC COMPONENT HYDROCORTISONE
Common Name English
CALMURID HC COMPONENT HYDROCORTISONE
Common Name English
SYNACORT
Brand Name English
NSC-10483
Code English
CORTRIL
Brand Name English
FLEXICORT
Code English
PYOCIDIN COMPONENT HYDROCORTISONE
Common Name English
BETA-HC
Brand Name English
ORLEX HC COMPONENT HYDROCORTISONE
Common Name English
ACETASOL HC COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF ACETASOL HC
Common Name English
VOSOL HC COMPONENT HYDROCORTISONE
Common Name English
CETACORT
Brand Name English
CORT-DOME
Brand Name English
DERMACORT
Brand Name English
HYDROCORTISONUM [WHO-IP LATIN]
Common Name English
BALNEOL-HC
Brand Name English
OTICAIR COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF ORLEX HC
Common Name English
CIPRO HC COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE [EP]
Common Name English
HYDROCORTISONE COMPONENT OF OTOCORT
Common Name English
HYDROCORTISONE [INN]
Common Name English
HYDROCORTISONE COMPONENT OF VOSOL HC
Common Name English
NUTRACORT
Brand Name English
ACTICORT
Brand Name English
PENECORT
Brand Name English
HYDROCORTISONE [HSDB]
Common Name English
HYDROCORTISONE COMPONENT OF PEDIOTIC
Common Name English
ELDECORT
Brand Name English
HYTONE
Brand Name English
ALA-SCALP
Brand Name English
HYDROCORTISONE COMPONENT OF ALPHADERM
Common Name English
ALPHADERM COMPONENT HYDROCORTISONE
Common Name English
11.BETA.,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
Systematic Name English
HYDROCORTISONE [WHO-DD]
Common Name English
ALA-CORT
Brand Name English
HYDROCORTISONE COMPONENT OF CIPRO HC
Common Name English
OTOBIOTIC COMPONENT HYDROCORTISONE
Common Name English
Classification Tree Code System Code
LIVERTOX 485
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S01CB03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QA01AC03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S02CA03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS01CA03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS03CA04
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.1662A
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 18.1
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QR01AD60
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S01CA03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
FDA ORPHAN DRUG 234906
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
EMA ASSESSMENT REPORTS PLENADREN (AUTHORIZED: ADRENAL INSUFFICIENCY)
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S03CA04
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QD07AA02
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS02BA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
EU-Orphan Drug EU/3/06/372
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS02CA03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC D07AA02
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QA07EA02
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.1484D
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QH02AB09
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QC05AA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC A01AC03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
FDA ORPHAN DRUG 487515
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS01BB01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.1132
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC R01AD60
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QD07XA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
NDF-RT N0000175576
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QD07BA04
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.1484I
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
EPA PESTICIDE CODE 6312
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
NDF-RT N0000175450
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS01BA02
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S01BB01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.1484H
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
FDA ORPHAN DRUG 467014
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC D07BA04
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC D07CA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC H02AB09
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S02BA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QD07CA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC A07EA02
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC C05AA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 17.3
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 13.3
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC S01BA02
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-ATC D07XA01
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
WHO-VATC QS01CB03
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.1204
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
NCI_THESAURUS C2323
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
CFR 21 CFR 524.155
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
FDA ORPHAN DRUG 441614
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
Code System Code Type Description
LactMed
50-23-7
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
RXCUI
5492
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY RxNorm
INN
38
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
DRUG BANK
DB00741
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
PUBCHEM
5754
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
WIKIPEDIA
CORTISOL
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
IUPHAR
2868
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
CAS
50-23-7
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
EVMPD
SUB08065MIG
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
MERCK INDEX
M6094
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY Merck Index
ChEMBL
CHEMBL389621
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
NCI_THESAURUS
C555
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HYDROCORTISONE
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water and ether R; sparingly soluble in ethanol (~750 g/l) TS and acetone R. Category: Adrenocortical steroid. Storage: Hydrocortisone should be kept in a well-closed container, protected from light. Additional information: Hydrocortisone melts at about 214?C with decomposition. Definition: Hydrocortisone contains not less than 97.0% and not more than 102.0% of C21H30O5, calculated with reference to the dried substance.
HSDB
50-23-7
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
EPA CompTox
50-23-7
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
ECHA (EC/EINECS)
200-020-1
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
MESH
D006854
Created by admin on Mon Oct 21 20:55:37 UTC 2019 , Edited by admin on Mon Oct 21 20:55:37 UTC 2019
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
2.4 FOLD INDUCTION OF GR MMTV-liciferase reporter gene
AGONIST
FOLD INDUCTION
TARGET -> AGONIST
2.4 FOLD INDUCTION OF GR MMTV-luciferase reporter gene
AGONIST
FOLD INDUCTION
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY